OATH BIOENGINEERING
Live / Applied — Non-final action mailed (as of 18 Mar 2026)
What this means for you
Not registered yet, but its 22 Oct 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99457465
- Mark type
- Stylized text
- Filed
- 22 Oct 2025
- Attorney of record
- Isaac M. Fine
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for alleviating side effects of cancer treatments; Pharmaceutical preparations for alleviating side effects of chemotherapy; Pharmaceutical preparations for alleviating side effects of radiation therapy; Pharmaceutical preparations for alleviating side effects of targeted cancer treatments; Pharmaceutical preparations for alleviating side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; Pharmaceutical preparations for alleviating side effects of immunotherapy treatments; Pharmaceutical preparations for alleviating gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; Pharmaceutical preparations for stimulating appetite; Pharmaceutical preparations for preventing weight loss; Pharmaceutical preparations for protecting bone marrow and the production of bone marrow; Pharmaceutical preparations for protecting stem cells and stimulating the production of stem cells; Pharmaceutical preparations for increasing resiliency of stem cells, increasing the number of stem cells, and preventing the reduction of stem cell populations; Pharmaceutical preparations for protecting blood cells, alleviating anemia, neutropenia, thrombocytopenia, and alleviating low blood counts; Pharmaceutical preparations for alleviating dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; Pharmaceutical preparations for the prevention and treatment of side effects of cancer treatments; Pharmaceutical preparations for the prevention and treatment of side effects of chemotherapy; Pharmaceutical preparations for the prevention and treatment of side effects of radiation therapy; Pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments; Pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; Pharmaceutical preparations for the prevention and treatment of side effects of immunotherapy treatments; Pharmaceutical preparations for the prevention and treatment of gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; Pharmaceutical preparations for the prevention and treatment of loss of appetite; Pharmaceutical preparations for the prevention and treatment of weight loss; Pharmaceutical preparations for the treatment and prevention of bone marrow damage; Pharmaceutical preparations for the treatment and prevention of stem cell damage and reduction of stem cell populations; Pharmaceutical preparations for the treatment and prevention of blood cell damage, anemia, and low blood count; Pharmaceutical preparations for the treatment and prevention of dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; Pharmaceutical preparations for the treatment and prevention of side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments, namely, reduced fertility; Pharmaceutical preparations for supporting stem cell health and production; Pharmaceutical preparations for supporting stem cell health and production, namely for stimulating uterine, bone marrow and gastrointestinal track stem cell production; Pharmaceutical preparations for the treatment of radiation exposure; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of inflammatory bowel disease, ulcerative colitis and other inflammatory bowel disorders; Pharmaceutical preparations for the enhancement of chemotherapy; Pharmaceutical preparations for the enhancement of immunotherapy; Fertility enhancement preparations
Owner
- Caper Labs, Inc., San Francisco, CA, US
Prosecution history
- 18 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 18 Mar 2026 — NON-FINAL ACTION E-MAILED
- 18 Mar 2026 — NON-FINAL ACTION WRITTEN
- 09 Mar 2026 — ASSIGNED TO EXAMINER
- 12 Dec 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 12 Dec 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 12 Dec 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 22 Oct 2025 — APPLICATION FILING RECEIPT MAILED
- 22 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 22 Oct 2025 — NEW APPLICATION ENTERED